$599

New Foundayo Campaign; Structure & Senseonics Q3 ’26 Earnings; New LillyDirect CMO; FDA Approves Bayer’s Sunharbo; Lilly initiates Ph2 Bimagrumab HFpHF study

A series of cardiometabolic-related news items has been observed from Lilly, Structure Therapeutics, Senseonics, and Bayer. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here